Goldman Sachs Says the Crowd Is Wrong on This Beaten-Down Medical Robotics Giant
Yahoo Finance ·
Intuitive Surgical ( ISRG 6.86% ) has faced challenges over the past 12 months, and its shares have declined by 26% during this period. However, some Wall Street analysts remain bullish on the stock, with several setting price targets that imply reasonable upside from current levels. Take David Roman, an analyst at Goldman Sachs ( GS +9.00% ) . He recently maintained a "buy" rating on the stock, giving it a 12-month price target of $558. That's 47% above Intuitive Surgical's current stock price. Should investors take Roman's advice and rush to buy the company's shares? Intuitive Surgical's recent headwinds include lower-than-expected margins tied to the rollout of the da Vinci 5, the latest version of its famous robotic-assisted surgery (RAS) system, launched in 2024. The da Vinci 5 has experienced strong adoption, but it comes with lower margins than previous versions. The medical device specialist is also dealing with steep tariffs, leading to rising costs. It's not clear that the company can solve these issues within the next six to 12 months. However, there are still great reasons to be bullish on Intuitive Surgical's long-term outlook. Consider the company's da Vinci 5. This newer product has several advantages over previous versions, including the Force Feedback Technology, which allows surgeons to feel the pressure and texture of tissue through the robotic controls, giving them a better sense of touch that could make delicate procedures safer, more precise, and easier to perform.
DYAX Investor Sentiment
Bullish (Long) 69% · Bearish (Short) 31%
424 participants
Related News
- OpenAI researcher Miles Wang departs to launch $2B AI drug discovery startup
- Earnings Snapshot: ASML beats across Q2 top and bottom lines, hikes full-year guidance and capacity target boosts
- ASML Holding in charts: Q2 net sales surge 21% Y/Y to €9.33B; gross profit hits €5.04B
- Q32 Bio prices $200M equity raise
- Rio Tinto Q2 iron ore sales rise 7%; lowers copper cost guidance
- Laird Superfood CFO to step down